Injection or arthroscopy — what determines the choice

Choosing between ChondroFiller as an outpatient injection and ChondroFiller delivered arthroscopically is not a question of how much intervention a patient is willing to accept. The fork in the road is determined by the joint itself — specifically, whether the damage is a well-contained focal defect or a more diffuse pattern of wear across the joint surface.

Both pathways use the same acellular Type I collagen scaffold. What differs is the anatomical logic of delivery. The ultrasound-guided injection route is additive: the gel is placed into a fluid joint environment, cushioning damaged surfaces from the top down — a pathway suited to Kellgren-Lawrence Grade III or IV osteoarthritis where widespread cartilage thinning is the underlying problem. The arthroscopic route works in the opposite direction: damaged tissue is first removed to stable borders in a dry operative field, and the scaffold is seated from the base up to rebuild a focal, structurally contained lesion.

Defect geometry, joint state, and patient profile are the clinical filters that determine which pathway applies — not patient preference alone.

Why cartilage cannot repair itself

Hyaline cartilage — the smooth, load-bearing tissue lining joint surfaces — is avascular, aneuric, and alymphatic. It has no direct blood supply, no nerve fibres running through it, and no lymphatic drainage. That triad of absences means the body's standard injury response never reaches a chondral defect: there is no haematoma, no inflammatory cascade, and no delivery of the circulating progenitor cells that normally begin tissue repair elsewhere in the body.

Left alone, a cartilage lesion does not fill in. Rest reduces load; physiotherapy rebuilds the musculature around the joint; anti-inflammatory injections can quieten pain. None of those measures replaces lost chondral structure, because the raw materials for repair — the stem cells — simply cannot migrate to the defect site without a physical route to travel.

A collagen scaffold addresses that gap directly. Placed within or across the defect, it provides a matrix through which progenitor cells from the synovium and subchondral bone can migrate and differentiate — a process termed acellular matrix-induced chondrogenesis. Whether that scaffold is placed under ultrasound guidance as an outpatient injection or seated arthroscopically in a dry operative field, the underlying biological principle is the same.

The outpatient ChondroFiller injection pathway

At London Cartilage Clinic, ChondroFiller is delivered as an outpatient, ultrasound-guided injection — no theatre admission, no general anaesthetic, and no surgical incision. The appointment takes place in clinic, with image guidance used to position 2.3 mL of the collagen scaffold precisely within the joint space.

This route is indicated for diffuse articular wear rather than surgically isolated focal lesions. Patients with Kellgren-Lawrence Grade III or IV osteoarthritis — where cartilage thinning is widespread rather than sharply bounded — are typically the appropriate candidates. In that environment, the scaffold gels in situ within the existing joint fluid, forming a mechanical cushion that also provides a matrix for progenitor cell migration from the surrounding synovial tissue.

Post-injection MRI has shown structural signal changes consistent with a therapeutic response: reduced bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. Functional measures — NRS pain scores, DASH questionnaire results, and grip and pincer strength testing — have also shown improvement in reported cases.

A longitudinal maintenance protocol has been proposed for this pathway: bi-annual ChondroFiller top-up injections, yearly peptide therapy, and annual MRI monitoring, with the aim of long-term joint preservation. This remains a clinical protocol rather than evidence-graded guidance; independent published RCT data for the injection route are not yet available. The evidence base is evolving, and peer-reviewed corroboration is an acknowledged next step for this pathway.

What arthroscopic ChondroFiller implantation involves

For patients with well-contained focal chondral defects — rather than the diffuse wear addressed by the injection pathway — ChondroFiller can alternatively be delivered arthroscopically in an operating theatre setting, under general or regional anaesthesia.

The surgical technique is subtractive rather than additive. A surgeon first removes unstable or damaged cartilage with a scalpel and curette, shaping the lesion to stable, perpendicular borders before thoroughly drying the joint. The collagen gel is then press-fitted approximately 2 mm below the surrounding articular surface, seating it flush within the prepared defect. That dry-field requirement is fundamental: unlike the injection route, which relies on the scaffold gelling within existing joint fluid, the arthroscopic approach needs direct mechanical contact with the lesion base from the outset.

This pathway suits isolated Grade III or IV chondral lesions with healthy surrounding tissue — defects that are surgically containable rather than distributed across the joint surface. A 2024 peer-reviewed study by Simeonov and colleagues, published in the Journal of IMAB, followed 17 patients (mean age 31 years) treated at University Hospital Pleven over the period 2012 to 2023. Lysholm and IKDC scores improved significantly at 3, 6, and 12 months (p<0.05), with functional recovery appearing to plateau between the six- and twelve-month assessments. The dataset is small and single-centre, so the findings should be read as encouraging rather than definitive.

The technique has also been extended to focal hip defects. A 2021 procedure paper described a bespoke needle-and-curette tool designed to ensure full collagen matrix contact in anatomically challenging hip lesions where standard instruments cannot reach reliably.

What the outcomes evidence shows — and where gaps remain

The comparative picture is clearer for the arthroscopic pathway than for the injection route, and it is worth being explicit about what each confidence level supports.

For the arthroscopic approach, expert analysis positions ChondroFiller as yielding approximately 30 points of IKDC improvement, with a complication rate of around 0% and reoperation in only 3–8% of cases. Those figures compare favourably with microfracture — which carries reoperation rates as high as 41% and produces fibrocartilage rather than hyaline-like repair tissue — and with ACI/MACI, a two-stage procedure associated with complication rates up to 17% and reoperation up to 37%. A 2022 meta-analysis of 876 patients (mean defect 3.91 cm², mean age 36.2 years) adds independent structural support: gel-based acellular scaffolds showed significantly lower rates of incomplete defect filling compared with multilayered (RR 0.78) and single-layered (RR 0.58) alternatives, with concentrated bone marrow aspirate augmentation further improving clinical scores across all scaffold formats.

For the injection pathway, the documented gains in bone marrow oedema, joint-space appearance, and patient-reported pain and function derive from platform-level clinical documentation rather than independent peer-reviewed trials. There is currently no published head-to-head RCT comparing the two ChondroFiller delivery routes directly, and durability data beyond two years for the injection pathway are absent at this stage. Evidence gaps of this kind are not unusual during the early lifecycle of a novel delivery method; what they mean practically is that injection-route claims carry lower certainty than the arthroscopic outcome benchmarks until peer-reviewed corroboration is published.

Getting assessed and deciding which pathway fits

Two broad candidacy profiles emerge from the evidence. Younger patients with a focal, well-contained chondral defect and preserved joint architecture are more likely to be directed towards the arthroscopic route, where mechanical containment makes direct scaffold implantation feasible. Those presenting with diffuse Kellgren-Lawrence Grade III or IV osteoarthritic change — or for whom theatre admission carries additional anaesthetic risk — are more likely to be considered for the outpatient injectable pathway instead.

Neither route is something a patient can or should self-select. Determining which (if any) applies requires a specialist assessment that includes imaging review, a clear picture of defect morphology, and an honest discussion of the evidence gaps outlined above.

London Cartilage Clinic, based on Harley Street, offers dedicated cartilage and joint-preservation assessments for patients weighing these options. To arrange an appointment, visit londoncartilage.com.

1. [1] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. (2021). https://doi.org/10.1016/j.eats.2021.03.011 https://doi.org/10.1016/j.eats.2021.03.011
3. [3] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
4. [4] Autologous minced cartilage repair for chondral and osteochondral lesions of the knee joint demonstrates good postoperative outcomes and low reoperation rates at minimum five-year follow-up. (2023). https://doi.org/10.1007/s00167-023-07546-1 https://doi.org/10.1007/s00167-023-07546-1
5. [5] Does the Choice of Acellular Scaffold and Augmentation With Bone Marrow Aspirate Concentrate Affect Short-term Outcomes in Cartilage Repair? A Systematic Review and Meta-analysis. (2022). https://doi.org/10.1177/03635465211069565 https://doi.org/10.1177/03635465211069565